Protection from neurodegeneration in the 6-hydroxydopamine (6-OHDA) model of Parkinson's with novel 1-hydroxypyridin-2-one metal chelators

Targeting Chelatable Iron as a Therapeutic Modality in Parkinson's Disease

(2013) David Devos et al.   ANTIOXIDANTS & REDOX SIGNALING

6-Hydroxydopamine promotes iron traffic in primary cultured astrocytes

(2013) Hao-Yun Zhang et al.   BIOMETALS

Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators

(2013) Orly Weinreb et al.   FREE RADICAL BIOLOGY AND MEDICINE

Design of iron chelators with therapeutic application

(2012) Tao Zhou et al.   DALTON TRANSACTIONS

Hydroxypyridinones as “privileged” chelating structures for the design of medicinal drugs

(2011) M. Amélia Santos et al.   COORDINATION CHEMISTRY REVIEWS

Different 8-Hydroxyquinolines Protect Models of TDP-43 Protein, α-Synuclein, and Polyglutamine Proteotoxicity through Distinct Mechanisms

(2011) Daniel F. Tardiff et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The Alzheimer’s therapeutic PBT2 promotes amyloid-β degradation and GSK3 phosphorylation via a metal chaperone activity

(2011) Peter J. Crouch et al.   JOURNAL OF NEUROCHEMISTRY

The potential application of iron chelators for the treatment of neurodegenerative diseases

(2011) Robert C. Hider et al.   Metallomics

Changes in iron-regulatory gene expression occur in human cell culture models of Parkinson’s disease

(2011) C.B. Carroll et al.   NEUROCHEMISTRY INTERNATIONAL

Metal Ionophore Treatment Restores Dendritic Spine Density and Synaptic Protein Levels in a Mouse Model of Alzheimer's Disease

(2011) Paul A. Adlard et al.   PLoS One

The emergence of designed multiple ligands for neurodegenerative disorders

(2011) Werner J. Geldenhuys et al.   PROGRESS IN NEUROBIOLOGY

Why Do We Need Multifunctional Neuroprotective and Neurorestorative Drugs for Parkinson's and Alzheimer's Diseases as Disease Modifying Agents

(2011) Moussa B. H. Youdim   Experimental Neurobiology

Synthesis, physical–chemical characterisation and biological evaluation of novel 2-amido-3-hydroxypyridin-4(1H)-ones: Iron chelators with the potential for treating Alzheimer’s disease

(2010) Alessandra Gaeta et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Up-regulation of divalent metal transporter 1 in 6-hydroxydopamine intoxication is IRE/IRP dependent

(2010) Hong Jiang et al.   CELL RESEARCH

Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson’s disease after peripheral administration

(2010) David T. Dexter et al.   JOURNAL OF NEURAL TRANSMISSION

Reconstruction and quantitative evaluation of dopaminergic innervation of striatal neurons in dissociated primary cultures

(2010) Seiko Wakita et al.   JOURNAL OF NEUROSCIENCE METHODS

Chemistry and biology of siderophores

(2010) Robert C. Hider et al.   NATURAL PRODUCT REPORTS

Chelation therapy for neurodegenerative diseases

(2009) Silvia Bolognin et al.   MEDICINAL RESEARCH REVIEWS

A novel transferrin/TfR2-mediated mitochondrial iron transport system is disrupted in Parkinson's disease

(2009) Pier Giorgio Mastroberardino et al.   NEUROBIOLOGY OF DISEASE

Brain iron pathways and their relevance to Parkinson's disease

(2003) D Berg et al.   JOURNAL OF NEUROCHEMISTRY